Value
4.4/10data confidence 83%| Component | Sub-score |
|---|---|
| P/E | 4.3 |
| P/S | 0.9 |
| Fwd P/E | 9.2 |
| PEG | 4.4 |
| Analyst target | 3.0 |
- ▸Forward P/E: 10.3x
- ▸PEG: 2.09
RPRX · Why this verdict
Why Royalty Pharma (RPRX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company has beaten earnings estimates in all 4 of the last 4 quarters, with an average positive surprise of approximately 10.6%, suggesting management sets conservative guidance that it reliably exceeds. Earnings | Earnings per share continues to exceed analyst consensus estimates in each of the next 4 quarters, sustaining the beat streak. | →Stable |
| CounterThe beat streak may reflect declining analyst expectations rather than genuine operational outperformance, and free cash flow running at negative 119% relative to net income signals a structural quality gap. | ||
A Piotroski F-Score of 8 out of 9 indicates strong balance sheet health and financial discipline across profitability, leverage, and operating efficiency dimensions. Quality breakdown | Piotroski score remains at 7 or above over the next 12 months, reflecting continued discipline in financial reporting and balance sheet management. | →Stable |
| CounterFree cash flow conversion is deeply negative at negative 119% relative to net income, calling into question the quality of reported earnings and offsetting the otherwise strong score. | ||
Analysts maintain a constructive view with a sentiment score of 6.6, though coverage is light at 8 analysts, which dampens the signal strength of the consensus. Sentiment breakdown | Analyst consensus rating remains above neutral, with no material downgrade cycle emerging over the next 12 months. | →Stable |
| CounterThe price has already reached the analyst target, leaving negative 5% upside to consensus, which makes a further re-rating higher dependent on target price increases rather than price appreciation. | ||
Price momentum is weak, with on-balance volume falling and the momentum score at 2.5, indicating net distribution by market participants despite positive earnings history. Momentum breakdown | Momentum score rises above 4.5 within 12 months as selling pressure abates and price builds a constructive base above the 200-day moving average. | →Stable |
| CounterThe stock is already near its 52-week high with falling on-balance volume, suggesting sellers are active at these levels and a momentum recovery may require a meaningful price pullback first. | ||
The company has beaten earnings estimates in all 4 of the last 4 quarters, with an average positive surprise of approximately 10.6%, suggesting management sets conservative guidance that it reliably exceeds.
→StableEarnings
- Expectation
- Earnings per share continues to exceed analyst consensus estimates in each of the next 4 quarters, sustaining the beat streak.
CounterThe beat streak may reflect declining analyst expectations rather than genuine operational outperformance, and free cash flow running at negative 119% relative to net income signals a structural quality gap.
A Piotroski F-Score of 8 out of 9 indicates strong balance sheet health and financial discipline across profitability, leverage, and operating efficiency dimensions.
→StableQuality breakdown
- Expectation
- Piotroski score remains at 7 or above over the next 12 months, reflecting continued discipline in financial reporting and balance sheet management.
CounterFree cash flow conversion is deeply negative at negative 119% relative to net income, calling into question the quality of reported earnings and offsetting the otherwise strong score.
Analysts maintain a constructive view with a sentiment score of 6.6, though coverage is light at 8 analysts, which dampens the signal strength of the consensus.
→StableSentiment breakdown
- Expectation
- Analyst consensus rating remains above neutral, with no material downgrade cycle emerging over the next 12 months.
CounterThe price has already reached the analyst target, leaving negative 5% upside to consensus, which makes a further re-rating higher dependent on target price increases rather than price appreciation.
Price momentum is weak, with on-balance volume falling and the momentum score at 2.5, indicating net distribution by market participants despite positive earnings history.
→StableMomentum breakdown
- Expectation
- Momentum score rises above 4.5 within 12 months as selling pressure abates and price builds a constructive base above the 200-day moving average.
CounterThe stock is already near its 52-week high with falling on-balance volume, suggesting sellers are active at these levels and a momentum recovery may require a meaningful price pullback first.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Royalty Pharma has demonstrated a consistent pattern of delivering earnings above analyst expectations across four straight quarters, but negative price momentum and a risk/reward profile tilted against new buyers suggest the stock's near-term opportunity has narrowed significantly.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 4.6 |
| ROA | 3.7 |
| Net margin | 10.0 |
| Current ratio | 9.0 |
| FCF quality | 0.0 |
| Moat | 6.9 |
| Rule of 40 | 3.0 |
| Piotroski F | 8.9 |
- ▸Strong margins: 34%
- ▸Earnings quality RED FLAG: -119% FCF/NI
- ▸Rule of 40: -29 (fail)
- ▸Strong Piotroski F-Score: 8/9
Growth
5.9/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.2 |
| EPS growth | 6.6 |
Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 9.5 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.3 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.2 |
| Analyst rating | 6.8 |
| Price target | 5.4 |
- ▸Light analyst coverage (8.0) — signal dampened
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $15,478,660 (0.047% of mkt cap)
Peer rank
4.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.9 |
| quality rank | 8.1 |
| growth rank | 4.8 |
- ▸Superior ROE vs peers
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.0 |
| 52w position | 10.0 |
Risk (lower is worse)
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.7 |
| days to cover | 8.2 |
| volatility | 6.0 |
| put call | 10.0 |
| implied vol | 4.4 |
| beta | 10.0 |
| debt equity | 5.6 |
Catalyst
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 7.8 |
| dividend safety | 4.8 |
| news activity | 7.0 |
- ▸Perfect beat streak: 4Q
- ▸Yield trap warning: high yield but unsafe
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- MOMENTUM:7.2>=5.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:33d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.9=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.94
Upside
-10.8%
Downside
11.5%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 60, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 5.4 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Risk (lower is worse) at 7.6) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.9=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.94 — supplementary context, not the trigger for this path.
The strongest dimensions are Risk (lower is worse) at 7.6, Momentum at 7.2, and Catalyst at 6.6; the weakest are Technical at 3.3, Insider at 3.8, and Peer rank at 4.2. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.94 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Consistent Earnings Beat Streak
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters, ending the beat streak.
- P2Piotroski Financial Strength
Trip ifFree cash flow as a percentage of net income falls below negative 150%, indicating further deterioration in earnings quality beyond the current negative 119%.
- P3Analyst Sentiment And Coverage
Trip ifAnalyst consensus price target drops below $50, more than 8% below the current price of $54.27.
- P4Negative Price Momentum Headwind
Trip ifMomentum score rises above 4.5 within 12 months, confirming a reversal of the current distribution trend.